Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 3,978 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Insulin Resistance, Cognitive Impairment
Interventions: Sleeve gastrectomy; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mild Cognitive Impairment
Interventions: Placebo, Candesartan; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Chronic Prostatitis (CP), Chronic Pelvic Pain Syndrome (CPPS), Painful Bladder Syndrome (PBS), Benign Frequency Syndrome (BFS), Interstitial Cystitis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions: Administration of autologous adipose derived SVF; Procedure
Lead sponsor: Elliot Lander; Industry
Eligibility: 16 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rancho Mirage, California

Conditions: Nonsmall Cell Lung Cancer
Interventions: Exercise; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 50 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Mild Cognitive Impairment
Interventions: Ketogenic diet, Healthy high carbohydrate diet; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 50 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions: Low-oxalate fixed diet; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Renal Impairment
Interventions: Elinogrel; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Chronic Granulomatous Diseases (CGD) and Liver Lesions
Interventions: Cool-tip RF Ablation System; Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Erectile Dysfunction, Sexual Dysfunction, Physiological
Interventions: Levitra (Vardenafil, BAY38-9456), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 11
States / cities: Laguna Hills, California • Jeffersonville, Indiana • Des Moines, Iowa + 8 more

Conditions: Delirium, Cognitive Impairment, Alzheimer; Early Onset, Trauma, Polytrauma, Traumatic Brain Injury, ICU, Critical Illness
Interventions: Non-interventional observational prospective cohort study; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
Interventions: CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alzheimer Disease (AD)
Interventions: Zagotenemab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Encino, California + 45 more

Conditions: Meibomian Gland Dysfunction (Disorder)
Interventions: TearCare®; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 29 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Chronic Kidney Disease
Interventions: Flow-mediated dilation, single blood draw; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado

Conditions: Hepatic Impairment, Healthy Volunteers
Interventions: PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Erectile Dysfunction
Interventions: RALP using full nerve sparing technique, dHACM Application; Procedure · Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Celebration, Florida

Conditions: Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions: Ranolazine; Drug
Lead sponsor: Saint Thomas Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Endothelial Dysfunction, Inflammation, Oxidative Stress
Interventions: Traditional hookah smoking, Electronic hookah vaping; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 39 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Niemann-Pick Disease, Type C
Interventions: Adrabetadex; Drug
Lead sponsor: Mandos LLC; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 12 more

Conditions: Depression
Interventions: Memantine HCL; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognition Disorders in Old Age, Cognitive Decline, Cognitive Deterioration
Interventions: Combination of 40Hz light and cognitive therapy (ALZLIFE); Device
Lead sponsor: Alzheimer's Light LLC; Industry
Eligibility: 50 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cognitive Impairment
Interventions: Meditative Movement; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 45 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pomona, California

Conditions: Aging, Aging Well, All-Cause Mortality, Mortality, Metabolic Syndrome, Cardiovascular Diseases, Cognitive Dysfunction, Musculoskeletal Diseases, Neoplasms, Frailty, Activities of Daily Living, Health-Related Quality of Life, Disability Physical, Neuro-Degenerative Disease, Dementia
Interventions: Comprehensive Multi-System Clinical Screening; Diagnostic Test
Lead sponsor: Longevity Metrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2099
U.S. locations: 1
States / cities: Boulder, Colorado

Search by objective public record fields.

Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

Genetic Study of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Skeletal Muscle Atrophy and Dysfunction in Human Cancer

Energy Metabolism and Cognitive Aging

Influence of Metabolic Syndrome on Endogenous Oxalate Synthesis

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease

Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study

A Pilot Randomized Controlled Trial: CoINTEGRATE

A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease

TearCare in Young Adults

Endothelial Microparticles: A Novel Marker of Vascular Dysfunction

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

The Cardiovascular Effects of Electronic Hookah Vaping

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

Clinical Trial of Memantine for Major Depression

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

Gene Expression, Meditative Movement, and Emotional Distress (GME)

100-Year Human Aging Study